This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Pyronaridine is a benzonaphthyridine derivative indicated in the treatment of acute malaria caused by P. falciparum or P. vivax in area with low rates of infection and low resistance to artemisinin.
- Generic Name
- Pyronaridine
- DrugBank Accession Number
- DB12975
- Background
Pyronaridine has been investigated for the treatment of Malaria.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Pyronaridine (DB12975)
- Weight
- Average: 518.06
Monoisotopic: 517.224453 - Chemical Formula
- C29H32ClN5O2
- Synonyms
- Pyronaridine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Acute falciparum malaria •••••••••••• •••••• •••••••• •••• •••••• ••• •• •••••• Treatment of Acute malaria caused by plasmodium vivax •••••••••••• •••••• •••••••• •••• •••••• ••• •• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetophenazine The risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Acetophenazine. Alimemazine The risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Alimemazine. Ambroxol The risk or severity of methemoglobinemia can be increased when Pyronaridine is combined with Ambroxol. Artemether The risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Artemether. Articaine The risk or severity of methemoglobinemia can be increased when Pyronaridine is combined with Articaine. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Pyronaridine tetraphosphate 2T289F9ACO Not Available YKUQEKXHQFYULM-UHFFFAOYSA-N - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image PYRAMAX TABLETS Pyronaridine tetraphosphate (180 MG) + Artesunate (60 MG) Tablet, film coated บริษัท ดีซีเอฟ เฮลท์แคร์ จำกัด 2017-10-10 Not applicable Thailand 
Categories
- ATC Codes
- P01BF06 — Artesunate and pyronaridine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 4-aminoquinolines. These are organic compounds containing an amino group attached to the 4-position of a quinoline ring system.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Aminoquinolines and derivatives
- Direct Parent
- 4-aminoquinolines
- Alternative Parents
- Chloroquinolines / Naphthyridines / p-Aminophenols / Aniline and substituted anilines / Phenylmethylamines / Benzylamines / Alkyl aryl ethers / Aminopyridines and derivatives / Aralkylamines / Primary aromatic amines show 8 more
- Substituents
- 4-aminoquinoline / Alkyl aryl ether / Amine / Aminophenol / Aminopyridine / Aniline or substituted anilines / Aralkylamine / Aromatic heteropolycyclic compound / Aryl chloride / Aryl halide show 26 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- TD3P7Q3SG6
- CAS number
- 74847-35-1
- InChI Key
- DJUFPMUQJKWIJB-UHFFFAOYSA-N
- InChI
- InChI=1S/C29H32ClN5O2/c1-37-26-9-8-24-28(33-26)27(23-7-6-21(30)16-25(23)32-24)31-22-14-19(17-34-10-2-3-11-34)29(36)20(15-22)18-35-12-4-5-13-35/h6-9,14-16,36H,2-5,10-13,17-18H2,1H3,(H,31,32)
- IUPAC Name
- 4-({7-chloro-2-methoxybenzo[b]1,5-naphthyridin-10-yl}amino)-2,6-bis[(pyrrolidin-1-yl)methyl]phenol
- SMILES
- COC1=NC2=C(NC3=CC(CN4CCCC4)=C(O)C(CN4CCCC4)=C3)C3=CC=C(Cl)C=C3N=C2C=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 5485198
- PubChem Substance
- 347829115
- ChemSpider
- 10647812
- BindingDB
- 53353
- ChEBI
- 135951
- ChEMBL
- CHEMBL35228
- ZINC
- ZINC000003882897
- Wikipedia
- Pyronaridine
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data4 Active Not Recruiting Treatment Malaria 1 somestatus stop reason just information to hide 4 Completed Treatment Malaria caused by Plasmodium falciparum 1 somestatus stop reason just information to hide 4 Unknown Status Treatment Burkina Faso / Malaria 1 somestatus stop reason just information to hide 4 Unknown Status Treatment Plasmodium Falciparum Malaria (Drug Resistant) 1 somestatus stop reason just information to hide 3 Completed Treatment Coronavirus Disease 2019 (COVID‑19) / Malaria 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, film coated - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0132 mg/mL ALOGPS logP 5.78 ALOGPS logP 4.22 Chemaxon logS -4.6 ALOGPS pKa (Strongest Acidic) 7.96 Chemaxon pKa (Strongest Basic) 10.08 Chemaxon Physiological Charge 2 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 73.75 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 147.74 m3·mol-1 Chemaxon Polarizability 57.85 Å3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 223.97961 predictedDeepCCS 1.0 (2019) [M+H]+ 226.33762 predictedDeepCCS 1.0 (2019) [M+Na]+ 232.43077 predictedDeepCCS 1.0 (2019)
Drug created at October 21, 2016 01:44 / Updated at June 12, 2021 10:54